Radiation and immunotherapy: Renewed allies in the war on cancer

Por Seung, Steven K., Curti, Brendan, Crittenden, Marka, Urba, Walter
Publicado em 2012

Comparison of proteomic and genomic analyses of vaccine cell lines shows men receiving prostate gvax immunotherapy develop increased humoral responses to common cell line proteins...

Por Hulett, Tyler, Puri, Sachin, Curti, Brendan, Urba, Walter J, Fox, Bernard A
Publicado no J Immunother Cancer (2014)

GMP-grade α-TEA lysine salt: a 28-Day oral toxicity and toxicokinetic study with a 28-Day recovery period in Beagle dogs

Por Guerrouahen, Bella S., Hahn, Tobias, Alderman, Zefora, Curti, Brendan, Urba, Walter, Akporiaye, Emmanuel T.
Publicado no BMC Cancer (2016)

Science gone translational: the OX40 agonist story

Por Weinberg, Andrew D., Morris, Nicholas P., Kovacsovics-Bankowski, Magdalena, Urba, Walter J., Curti, Brendan D.
Publicado em 2011

Phase I/II clinical trial of anti-OX40, radiation and cyclophosphamide in patients with prostate cancer: immunological analysis

Por Kovacsovics-Bankowski, Magdalena, Chisholm, Lana, Vercellini, Jonna, Crittenden, Marka, Lary, Scot, Curti, Brendan, Weinberg, Andrew
Publicado em 2013

Phase I study of alpha-tocopherlyoxyacetic acid in patients with advanced cancer

Por Curti, Brendan D, Akporiaye, Emmanuel, Sutcliffe, Kim, Bahjat, Keith S, Koguchi, Yoshinobu, Cramer, Julie, Urba, Walter
Publicado no J Immunother Cancer (2015)

Development and Characterization of Recombinant Human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain

Por Morris, Nicholas P., Peters, Carmen, Montler, Ryan, Hu, Hong-Ming, Curti, Brendan D., Urba, Walter J., Weinberg, Andrew D.
Publicado em 2007

Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment

Por Andtbacka, Robert HI, Curti, Brendan D, Hallmeyer, Sigrun, Feng, Zipei, Paustian, Christopher, Bifulco, Carlo, Fox, Bernard, Grose, Mark, Shafren, Darren
Publicado no J Immunother Cancer (2015)

Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program

Por Payne, Roxanne, Glenn, Lyn, Hoen, Helena, Richards, Beverley, Smith, John W, Lufkin, Robert, Crocenzi, Todd S, Urba, Walter J, Curti, Brendan D
Publicado em 2014

An evaluation of autologous tumor-reactive TIL generation from head and neck squamous cell cancers

Por Mougdil, Tarsem, Paustian, Christopher, Feng, Zipei, Leidner, Rom, Dubay, Christopher, Curti, Brendan D, Hu, Hong-Ming, Urba, Walter, Bifulco, Carlo, Fox, Bernard, Bell, Brian
Publicado no J Immunother Cancer (2015)

Evaluation of circulating tumor cell gene expression profiles before and following combination immunotherapy for advanced prostate cancer

Por Puri, Sachin, Han, Jing, Joshi, Bharat H, Healy, Daniel, Siebert, Janet, Paustian, Christopher, Dubay, Christopher, Bahjat, Keith S, Curti, Brendan, Urba, Walter J, Fox, Bernard A
Publicado no J Immunother Cancer (2014)

Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma

Por Feng, Zipei, Puri, Sachin, Moudgil, Tarsem, Wood, William, Hoyt, Clifford C., Wang, Chichung, Urba, Walter J., Curti, Brendan D., Bifulco, Carlo B., Fox, Bernard A.
Publicado no J Immunother Cancer (2015)

Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy

Por Friedman, David J, Young, Kristina, Baird, Jason R, Cottam, Benjamin, Savage, Talicia, Newell, Pippa, Kasiewicz, Melissa, Redmond, William, Curti, Brendan, Crocenzi, Todd, Gough, Michael J, Crittenden, Marka
Publicado no J Immunother Cancer (2014)

Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy

Por Sckisel, Gail D., Mirsoian, Annie, Minnar, Christine M., Crittenden, Marka, Curti, Brendan, Chen, Jane Q., Blazar, Bruce R., Borowsky, Alexander D., Monjazeb, Arta M., Murphy, William J.
Publicado no J Immunother Cancer (2017)

Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab

Por Koguchi, Yoshinobu, Hoen, Helena, Bambina, Shelly, Rynning, Michael, Fuerstenberg, Richard, Feng, Zipei, Fox, Bernard, Bifulco, Carlo, Curti, Brendan D, Urba, Walter, Milburn, Christina, Korman, Alan J, Bahjat, Keith S
Publicado no J Immunother Cancer (2015)

Characterizing the immunoprofile and endogenous immune response to squamous cell carcinomas of the head and neck to guide development of effective immunotherapy strategies

Por Moudgil, Tarsem, Bell, R Bryan, Leidner, Rom, Feng, Zipei, Paustian, Christopher, Dubay, Christopher, Hilton, Traci L, Curti, Brendan, Urba, Walter J, Bifulco, Carlo B, Hu, Hong-Ming, Fox, Bernard A
Publicado no J Immunother Cancer (2014)

Novel strategy to monitor apparent tumor-specific T cells in patients with cancer

Por van de Ven, Rieneke, Hilton, Traci L, Dubay, Christopher J, Puri, Sachin, Hu, Hong-Ming, Leidner, Rom S, Bell, R Bryan, Urba, Walter J, Curti, Brendan D, Aung, Sandra, Fox, Bernard A
Publicado em 2013

A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (procliv...

Por Clark, Joseph, Flaherty, Lawrence, Ernstoff, Marc, Koon, Henry, Milhem, Mohammed, Militello, Gerald, Agarwala, Sanjiv, Curti, Brendan, Cranmer, Lee, Lao, Christopher D, Logan, Theodore F, Lutzky, Jose, Rudrapatna, Venkatesh, Daniels, Gregory, Taback, Bret, Aung, Sandra, Lowder, James, Lawson, David
Publicado no J Immunother Cancer (2014)

Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study

Por Bhatia, Shailender, Curti, Brendan, Ernstoff, Marc S, Gordon, Michael, Heath, Elisabeth I, Miller, Wilson H, Puzanov, Igor, Quinn, David I, Flaig, Thomas W, VanVeldhuizen, Peter, Byrnes-Blake, Kelly, Freeman, Jeremy A, Bittner, Rachel, Hunder, Naomi, Souza, Sonia, Thompson, John A
Publicado em 2014

A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States

Por Flaherty, Lawrence, Hamid, Omid, Linette, Gerald, Schuchter, Lynn, Hallmeyer, Sigrun, Gonzalez, Rene, Cowey, C. Lance, Pavlick, Anna, Kudrik, Fred, Curti, Brendan, Lawson, David, Chapman, Paul B., Margolin, Kim, Ribas, Antoni, McDermott, David, Flaherty, Keith, Cranmer, Lee, Hodi, F. Stephen, Day, Bann-Mo, Linke, Rolf, Hainsworth, John
Publicado no Cancer J (2014)